News brief­ing: Spring­Works, Jazz ex­change $35M and PTSD drug; Dr. Red­dy's says cy­ber­at­tack was ran­somware

Jazz Phar­ma­ceu­ti­cals is grab­bing an ex-Pfiz­er drug to beef up its mid-stage neu­ro­science port­fo­lio, pay­ing Spring­Works $35 mil­lion in cash for a new med for post-trau­mat­ic stress dis­or­der.

PF-04457845 is a FAAH in­hibitor that was orig­i­nal­ly test­ed for os­teoarthri­tis. But Spring­Works — and now Jazz — has po­ten­tial to ad­dress mul­ti­ple core symp­toms of PTSD, in­clud­ing fear ex­tinc­tion, anx­i­ety and dis­rupt­ed sleep ar­chi­tec­ture.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.